The Medicines Manufacturing Innovation Centre is a collaboration between CPI, University of Strathclyde, UK Research & Innovation, Scottish Enterprise and founding industry partners, AstraZeneca and GSK.
The centre will ensure the UK is a technology and innovation leader in pharmaceutical manufacturing. The initial focus will be on technology translation for small molecule drug manufacture.
With a collaborative innovation culture and state-of the art facilities, the new facility will enable industry, academia, healthcare providers and regulators to work collaboratively to address challenges and maximise technology opportunities within the medicines supply chain.
The works consist of the design and construction of a new build Medicines Manufacturing Innovation Centre (MMIC) with internal area of approximately 6,500 m2, the centre will be a two-storey steel frame building sitting on piled foundations.
The works will provide a top quality, highly technical centre which will include laboratories, ISO8 pharmaceutical cleanrooms and GMP compliant supporting activities.
The works will be at the stage of internal fit out with clean rooms under construction and the office and events space progressing. Plant rooms will be in progress with service installations ongoing throughout
Information on Open Doors 2022 will be released shortly